Supernus Pharmaceuticals (SUPN) Raw Materials (2012 - 2026)

Supernus Pharmaceuticals (SUPN) has 15 years of Raw Materials data on file, last reported at $31.5 million in Q1 2026.

• Raw Materials for Q1 2026 came in at $31.5 million, up 263.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $31.5 million (up 263.26% YoY), and the FY2025 annual result was $31.8 million, up 186.09% from the prior year.
• Raw Materials retreated to $31.5 million in Q1 2026 per SUPN's latest filing, from $31.8 million in the prior quarter.
• Over five years, Raw Materials peaked at $57.0 million in Q3 2025 and troughed at $7.5 million in Q2 2022.
• A 5-year average of $19.8 million and a median of $16.3 million in 2023 frame the typical range for Raw Materials.
• The sharpest annual moves came in 2022 and 2025: Raw Materials plunged 73.5% in 2022, then surged 392.51% in 2025.
• A 5-year view of Raw Materials shows it stood at $24.8 million in 2022, then slumped by 34.43% to $16.3 million in 2023, then plunged by 31.63% to $11.1 million in 2024, then soared by 186.09% to $31.8 million in 2025, then declined by 1.13% to $31.5 million in 2026.
• Business Quant data shows SUPN's Raw Materials at $31.5 million in Q1 2026, $31.8 million in Q4 2025, and $57.0 million in Q3 2025.